Nguyen Pho, Barte Felise, Shinada Shuntaro, Yiu Samuel C
Doheny Eye Institute and the Department of Ophthalmology, Keck School of Medicine of the University of Southern California, Los Angeles, CA 90033, USA.
J Clin Exp Ophthalmol. 2010 Sep 29;1(103). doi: 10.4172/2155-9570.1000103.
To report long-term results in a case series of patients treated with systemic immune suppression for prevention of penetrating keratoplasty (PKP) graft rejection. DESIGN: Retrospective noncomparative chart review. PARTICIPANTS: Three patients presented with PKP graft failure. METHODS: Patients received oral prednisone, azathioprine and cyclosporine to prevent rejection of repeat corneal transplant. Patients received repeat PKP and graft outcome was reported. MAIN OUTCOME MEASURES: Visual acuity and graft survival were recorded. RESULTS: Mean age was 55 years, two male and one female. Mean follow-up period was 37 months (range 24-46). All three patients completed the treatment protocol with minimal adverse effects. All grafts remained clear over observational period. CONCLUSION: Our study suggests that systemic immune suppression with 2 or more agents may be helpful to prevent corneal graft rejection in high-risk patients.
报告一系列接受全身免疫抑制治疗以预防穿透性角膜移植术(PKP)移植物排斥反应患者的长期结果。
回顾性非对照图表审查。
三名出现PKP移植物失败的患者。
患者接受口服泼尼松、硫唑嘌呤和环孢素以预防再次角膜移植的排斥反应。患者接受再次PKP并报告移植物结果。
记录视力和移植物存活情况。
平均年龄55岁,两名男性和一名女性。平均随访期为37个月(范围24 - 46个月)。所有三名患者均完成治疗方案,且不良反应最小。在观察期内所有移植物均保持透明。
我们的研究表明,使用两种或更多药物进行全身免疫抑制可能有助于预防高危患者的角膜移植物排斥反应。